Characterization of ornidazole metabolites in human bile after intraveneous doses by ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry  by Du, Jiangbo et al.
Chinese Pharmaceutical AssociationInstitute of Materia Medica, Chinese Academy of Medical Sciences
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2012;2(2):159–1672211-3835 & 2012 In
hosting by Elsevier B
Peer review under res
doi:10.1016/j.apsb.20
nCorresponding au
E-mail addresses:www.elsevier.com/locate/apsb
www.sciencedirect.comORIGINAL ARTICLE
Characterization of ornidazole metabolites in human bile
after intraveneous doses by ultraperformance liquid
chromatography/quadrupole time-of-ﬂight
mass spectrometryJiangbo Dua, Pan Denga, Xiaoyan Chena, Haidong Wanga,
Tiangeng Youb,n, Dafang Zhonga,naShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
bShanghai East Hospital, Shanghai 200120, China
Received 27 December 2011; revised 1 January 2012; accepted 12 January 2012KEY WORDS
Ornidazole;
UPLC/Q-TOF MS;
LC–MS/MS;
Human bile;
Metabolitestitute of Materia M
.V. All rights rese
ponsibility of Insti
12.01.002
thors. Tel./fax: þ8
tiangengyou@yahAbstract Ultraperformance liquid chromatography/quadrupole time-of-ﬂight mass spectrometry
(UPLC/Q-TOF MS) was used to characterize ornidazole metabolites in human bile after intravenous
doses. A liquid chromatography tandem mass spectrometry (LC–MS/MS) assay was developed for the
determination of the bile level of ornidazole. Bile samples, collected from four patients with T-tube
drainage after biliary tract surgery, were prepared by protein precipitation with acetonitrile before
analysis. A total of 12 metabolites, including 10 novel metabolites, were detected and characterized. The
metabolites of ornidazole in human bile were the products of hydrochloride (HCl) elimination, oxidative
dechlorination, hydroxylation, sulfation, diastereoisomeric glucuronation, and substitution of NO2 or Cl
atom by cysteine orN-acetylcysteine, and oxidative dechlorination followed by further carboxylation. The
bile levels of ornidazole at 12 h after multiple intravenous infusions were well above its minimal inhibitory
concentration for common strains of anaerobic bacteria.
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Jiangbo Du et al.1601. Introduction
Ornidazole is a nitro-imidazole derivative with antiprotozoal
and antibacterial activities against anaerobic bacteria1. The
antimicrobial activity of this drug is due to the reduction of
the nitro group to reactive intermediates that attack microbial
DNA2,3.
The elimination of ornidazole primarily depends on hepatic
metabolism4. However, the biotransformation of ornidazole is
poorly understood, and only a few investigations have
reported its metabolism. Schwartz et al.5 have studied the
metabolism of ornidazole in rats, dogs, and humans. After
oral administration of 750 mg of 14C-ornidazole (49.5 mCi),
ﬁve metabolites are identiﬁed in human urine. These are
1-chloro-3-(2-hydroxymethyl-5-nitro-1-imidazolyl)-2-propanol;
2-methyl-5-nitro-imidazole; N-(3-chloro-2-hydroxypropy)aceta-
mide; 3-(2-methyl-5-nitro-1-imidazolyl)-1,2-propanediol and
acetamide (Fig. 1). Currently, ornidazole is widely used in the
treatment and prophylaxis of susceptible anaerobic infections
after biliary tract surgery. Given its extensive clinical use, its
metabolism needs to be characterized more completely. Up to
now, the metabolites of ornidazole in human bile have not been
investigated.
The primary objective of the current study was to char-
acterize the metabolites of ornidazole in human bile using
UPLC/Q-TOF MS. Furthermore, the ornidazole level in bile
ﬂuid was determined by LC–MS/MS to prove its clinical
effectiveness.2. Materials and methods
2.1. Chemicals
Ornidazole (500 mg) and S-ornidazole (500 mg) injections
were products of Sanhome Pharmaceutical Co., Ltd. (Nanjing,
China). Reference standards of ornidazole and tinidazole were
purchased from the National Institute for the Control of
Pharmaceutical and Biological Products (Beijing, China).
b-Glucuronidase (from Escherichia coli, type IX-A, 1,661 U/mg;
from Helix pomatia, type H-2, 100,000 U/mL) were purchased
from Sigma–Aldrich (St. Louis, MO, USA). Methanol and
acetonitrile used for the chromatographic analysis were of
HPLC grade (Merck, Darmstadt, Germany). Puriﬁed water
was generated using a Milli-Q Gradient Water Puriﬁcation
System (Molsheim, France).Figure 1 Ornidazole metabolites identiﬁed in human urine after
oral administration5.2.2. Methods
2.2.1. Subjects and sample collection
The present study was approved by the ethics committee of
Shanghai East Hospital (Shanghai, China), performed in full
compliance with the Helsinki declaration, and consistent with
the principles of Good Clinical Practice. Patients after biliary
tract surgery were enrolled after giving informed consent.
After multiple intravenous infusions of 500 mg of ornidazole
at intervals of 12 h for three courses to four patients (one male
and three females), all bile post-doses were collected. Bile
samples at 12 h post-doses were separately collected. After the
intravenous infusion of 500 mg of S-ornidazole to two patients
(one male and one female), all bile were collected up to 12 h
post-dose. The samples were collected through a T-tube, and
then stored at 20 1C until analysis.
2.2.2. Bile sample preparation and b-glucuronidase hydrolysis
A 600 mL aliquot of acetonitrile was added to 200 mL of mixed
bile sample. The mixture was vortex-mixed and centrifuged at
11,000 g for 5 min. The supernatant was transferred into a
clean glass tube, and then evaporated to dryness under a
stream of air at 40 1C. The residue was reconstituted in 100 mL
of 0.05% formic acid in 5 mM ammonium acetate solution. A
5 mL aliquot of the reconstituted extract was injected into a
UPLC/Q-TOF MS system for metabolite characterization.
For enzymatic incubation, 200 mL of b-glucuronidase from
E. coli (2000 units, in phosphate buffered saline, pH¼7.4) or
H. pomatia (2000 units, in citrate buffer, pH¼5.0) were added
to a 200 mL aliquot of mixed bile sample, respectively. The
incubation was performed at 37 1C for 16 h. The effect of
glucuronidase was investigated by comparing the LC–MS
peak intensities of the glucuronide conjugates and the parent
drug before and after the enzymatic incubation.
For the determination of ornidazole in bile, a 25 mL of
aliquot of the internal standard (IS, 1.00 mg/mL tinidazole
solution) and 25 mL of methanol were added to 25 mL of bile
sample collected at 12 h post-doses. The sample mixture was
deproteinized with 100 mL of acetonitrile. The precipitate was
removed via centrifugation at 11,000 g for 5 min. After
evaporation to dryness, the supernatant was reconstituted
in 100 mL of 10 mM ammonium formate and acetonitrile
(96:4, v/v). A 10 mL aliquot of the reconstituted extract was
injected into an LC–MS/MS system for quantiﬁcation.
2.2.3. UPLC/Q-TOF MS analysis
Chromatographic separation was performed on an Acquity
UPLC HSS T3 column (1.8 mm, 100 mm 2.1 mm; Waters)
thermostated at 45 1C using a Waters Acquity UPLC system
(Waters Corp., Milford, MA, USA). The mobile phase was a
mixture of 0.05% formic acid in 5 mM ammonium acetate
solution (A) and methanol (B). The gradient elution started
from 1% B, linearly increased to 20% B in 13 min, linearly
increased to 90% B over the next 1 min, maintained at 90% B
for 2 min, and then decreased to 1% B to re-equilibrate the
column. The ﬂow rate was 0.4 mL/min, and the analytes were
monitored by UV detection at 318 nm.
MS detection was conducted using a Synapt Q-TOF MS
(Waters, USA) operated in the positive mode via an electro-
spray ionization interface. Nitrogen and argon were used as
the desolvation gas and collision gas, respectively. The
Figure 2 Mass spectra of the reference substance ornidazole
under high CE, and the tentative structures of fragment ions.
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respectively. The desolvation gas (nitrogen) was set to 800 L/h
at 350 1C, and the source temperature was kept at 100 1C.
Data were acquired from 50 Da to 1000 Da and corrected
during acquisition using an external reference (LockSpray)
comprised of 400 ng/mL leucine enkephalin (m/z 556.2771)
infused at 20 mL/min. An MSE scan function was programmed
with two independent collision energies (CEs)6. At low CE, the
transfer and trap CEs were 3 and 5 eV, respectively. At high
CE, the transfer CE was 10 eV and the trap CE ramped from
10 eV to 15 eV. Data acquired in this manner allowed for the
collection of intact precursor ion and fragment ion informa-
tion in a single run.
The mass spectra of the bile samples were compared with
the blank bile using the MetaboLynx software. Mass defect
ﬁltering (MDF) was used to screen the metabolites using a
ﬁlter of 40 mDa between the ﬁlter template and the target
metabolites. Comparison of the fragment ion spectra of the
parent compound and metabolites further aided the identiﬁca-
tion of metabolite structures and site(s) of modiﬁcations in the
parent molecule.
2.2.4. LC–MS/MS analysis
HPLC was performed using an Agilent Technologies 1200
series system equipped with a G1322A degasser, a G1312B SL
binary pump, a G1357D high-performance autosampler
(HiP ALS SLþ) and a G1316B SL thermostated column
compartment (Agilent, St. Clara, CA, USA). The analytes
were separated on a Synergi Hydro-RP column (4 mm, 50 mm
2.0 mm; Phenomenex, USA). The mobile phase comprised
10 mM ammonium formate solution (A) and acetonitrile (B).
The gradient elution started from 4% B, linearly increased to
40% B in 2 min, and then decreased to 4% B to re-equilibrate
the column.
A 6460 triple–quadrupole mass spectrometer (Agilent) was
operated with an atmospheric pressure chemical ionization
source in the positive mode. An Agilent Mass Hunter work-
station was used to control the equipment, data acquisition,
and analysis. The instrument was operated with a capillary
voltage of þ4.5 kV and a vaporizer temperature of 400 1C.
The corona discharge current was set to 4.0 mA. Nitrogen was
used as the nebulizer gas at 20 psi, as well as the carrier gas at
5 L/min and 325 1C. Multiple reaction monitoring (MRM)
was employed for data acquisition. The optimized MRM
fragmentation transitions were m/z 220-m/z 128, with a
fragmenter voltage of 120 V and a CE of 12 V for ornidazole,
m/z 248-m/z 128 with a fragmenter voltage of 120 V and a
CE of 30 V for the IS. The dwell time for each transition was
120 ms.3. Results
3.1. UPLC/Q-TOF MS analysis of ornidazole
To characterize ornidazole metabolites, the chromatographic
and MS fragmentation behaviors of the parent compound
were ﬁrst investigated. Under the present chromatographic
conditions, ornidazole was eluted at 13.7 min and formed a
protonated molecule [MþH]þ at m/z 220.049. The mass
spectrum of ornidazole under the high CE scan is shown in
Fig. 2. The main fragment ions were observed at m/z 128.043(100% abundance) and 82.050. The elemental composition of
these fragment ions was elucidated by the measured accurate
mass. The major fragment ion at m/z 128.043 was formed by
the cleavage of the C–N1 bond of the imidazole ring. Further
loss of nitro free radical produced the fragment ion at m/z
82.050. According to this fragment pattern, the structure of
ornidazole was divided into two parts: A and B (Fig. 2). The
presence of chlorine isotope peaks (abundance ratioE3:1)
indicates the existence of part A and this can be used for rapid
screening of metabolites. The detection of fragment ions at
m/z 128.043 and 82.050, as well as their relevant ions in the
high CE mass spectra indicates the presence of part B in
metabolites. The high CE mass spectra and chromatographic
behaviors of the detected metabolites were compared with
those of the parent compound to characterize the structural
modiﬁcation.
3.2. Metabolite characterization
The MDF technique and generic dealkylation tool were used
to screen the metabolites7,8. Compared with the blank bile, 12
metabolites of ornidazole were detected in human bile. Typical
metabolite chromatograms are shown in Fig. 3. Table 1 lists
the detailed information of these metabolites, including the
retention times, proposed elemental compositions and accu-
rate mass. The mass spectra and proposed mass fragmentation
patterns of detected metabolites are shown in Fig. 4. The
proposed metabolic pathways of ornidazole in human bile are
shown in Fig. 5.
Parent Drug M0: A chromatographic peak at 13.7 min was
detected in human bile, with an elemental composition of
C7H10ClN3O3 and a protonated molecular weight of 220.049.
The retention time and mass spectral fragmentation
patterns were identical to those of the parent drug ornidazole,
indicating that this compound was unchanged ornidazole,
designated as M0.
Metabolite M1: Metabolite M1 was eluted at 10.0 min. Its
protonated molecular weight was 184.072 and its elemental
composition was C7H9N3O3, indicating a loss of HCl from
ornidazole. High CE analysis revealed product ions at m/z
128.046 and 82.053, indicating that part B was intact. There-
fore, metabolite M1 was proposed as 1-(2-methyl-5-nitro-1H-
imidazol-1-yl)propan-2-one. The absence of chlorine isotope
peaks was consistent with the modiﬁcation of part A.
Metabolite M2: Metabolite M2 had a retention time of
6.4 min, exhibited a protonated molecule at m/z 202.083, and
Figure 3 Typical metabolite proﬁles of ornidazole in human bile after multiple intravenous infusions: (A) MDF metabolite proﬁle and
(B) UPLC-UV chromatography.
Table 1 Characterization of ornidazole metabolites in human bile.
Metabolite Description Measured
mass
Calculated
mass
ppm Formula Retention
time/min
M0 Parent 220.049 220.049 1.7 C7H10ClN3O3 13.7
M1 HCl elimination 184.072 184.072 2.7 C7H9N3O3 10.0
M2 Oxidative dechlorination 202.082 202.083 2.3 C7H11N3O4 6.4
M3 Carboxylation of M2 216.062 216.062 1.5 C7H9N3O5 4.3
M4 Hydroxylation 236.043 236.044 1.7 C7H10ClN3O4 9.5
M5 Substitution of NO2 by cysteine 294.067 294.068 3.1 C10H16ClN3O3S 2.0
M6 Sulfation 300.005 300.006 3.0 C7H10ClN3O6S 11.7
M7 Substitution of Cl by cysteine 305.092 305.092 1.3 C10H16N4O5S 5.7
M8 Substitution of NO2 by N-acetylcysteine 336.078 336.078 0.8 C12H18ClN3O4S 7.2
M9 Substitution of Cl by N-acetylcysteine 347.103 347.103 0.6 C12H18N4O6S 12.3
M10-1 Glucuronization 396.080 396.081 3.4 C13H18ClN3O9 11.1
M10-2 Glucuronization 396.080 396.081 1.7 C13H18ClN3O9 12.8
M11 Glucuronization of M4 412.075 412.076 1.4 C13H18ClN3O10 7.0
Jiangbo Du et al.162had an elemental composition of C7H11N3O4. This ﬁnding
suggested the addition of OH and loss of Cl from the parent
drug. The major fragment ions at m/z 128.043 and 82.051 were
the same as those of protonated ornidazole, suggesting the
intactness of part B. Therefore, metabolite M2 was proposed
to be 3-(2-methyl-5-nitro-1-imidazolyl)-1,2-propanediol, which
has been previously identiﬁed in human urine.
Metabolite M3: Metabolite M3 was eluted at 4.3 min with a
protonated precursor ion at m/z 216.062. Accurate mass
measurement revealed the formula C7H9N3O5, indicating the
introduction of an oxygen atom with dehydrogenation to M2.
The major fragment ions were observed at m/z 128.044 and
82.052, indicating that oxidation occurred on part A.Therefore, M3 was tentatively identiﬁed as a 30-carboxylation
metabolite of M2.
Metabolite M4: M4 was eluted at 9.5 min. It had a
protonated molecular weight of 236.044 and its elemental
composition was C7H10ClN3O4, indicating that an oxygen
atom was introduced into the parent drug. The fragment
ion at m/z 144.037 was 16 Da higher than the major fragment
ion at m/z 128.043 of protonated ornidazole, suggesting
that oxidation occurred on part B. The fragment ion at
m/z 126.027 was derived from the neutral loss of a H2O
molecule, indicating the formation of an aliphatic hydroxyl
group in part A of the parent drug. Therefore, M4 was
proposed as a 6-hydroxylation metabolite of ornidazole,
Characterization of ornidazole metabolites in human bile by UPLC/Q-TOF MS 1631-chloro-3-(2-hydroxymethyl-5-nitro-1-imidazolyl)-2-propanol,
which has been previously identiﬁed in human urine.
Metabolite M5: Metabolite M5 had a retention time of
2.0 min, exhibited a protonated molecule at m/z 294.068, and
had a derived formula of C10H16ClN3O3S, indicating the
addition of a cysteine and loss of NO2 from protonated
ornidazole. The major fragment ions were at m/z 248.063/
250.059, 207.034/209.032, and 115.032. The fragment ions at
m/z 248.063/250.059 were derived from the neutral loss of a
formic acid. Cleavage of the C–S bond produced the fragment
ion at m/z 248.063/250.059, and further cleavage of the C–N1
bond generated the fragment ion at m/z 115.032. Therefore,
M4 was tentatively identiﬁed as a cysteine S-conjugate of
ornidazole derived from the substitution of NO2 by cysteine.Figure 4 Mass spectra of ornidazole metabolites in humMetabolite M6: Metabolite M6 was eluted at 11.7 min with a
precursor ion at m/z 300.006 and an elemental composition of
C7H10ClN3O6S. M6 had a pair of major fragment ions at m/z
220.049/222.048, indicating a neutral loss of the sulfate group.
Further loss of H2O produced the fragment ion at m/z 202.038.
The other fragment ions at m/z 128.044 and 82.052 were the
same as those of the parent drug. Therefore, M6 was assumed
as a sulfate conjugate of ornidazole on the 20-hydroxyl.
Metabolite M7: Metabolite M7 had a retention time of
5.7 min, exhibited a protonated molecule at m/z 305.092, and
had a derived formula of C10H16N4O5S, indicating the addi-
tion of a cysteine and loss of a Cl atom from protonated
ornidazole. The fragment ion at m/z 178.052 was derived
from the loss of part B. The fragment ion at m/z 128.045an bile and proposed mass fragmentation pathways.
Figure 4 (continued)
Jiangbo Du et al.164indicated that modiﬁcation occurred on part A. Cleavage of
the C–S bond produced the fragment ion at m/z 88.038.
Therefore, M4 was tentatively identiﬁed as a cysteine
S-conjugate of ornidazole derived from the substitution of
Cl atom by cysteine.
Metabolite M8: Metabolite M8 was eluted at 7.2 min, and
had a precursor ion at m/z 336.078, which was 42 Da higher
than that of M5. Its elemental composition was C12H18N4O6S,
indicating the addition of COCH2 to M5. The fragment ion at
m/z 294.067 was identical to protonated M5, derived from the
loss of acetyl. The other fragment ions were the same as those
of M5. M8 was tentatively identiﬁed as a conjugate metabolite
derived from the substitution of NO2 by N-acetylcysteine.
Metabolite M9: Metabolite M9, eluted at 12.3 min, had a
protonated molecular weight of 347.103, which was 42 Da
higher than M7. The elemental composition of the metabolite
was C12H18N4O6S, indicating the addition of COCH2 to M7.The fragment ion at m/z 178.048 was identical to protonated
M7, derived from the loss of acetyl and part B. The fragment
ions at m/z 130.049 was 42 Da higher than that at m/z 88.038
of M7, indicating N-acetylcysteine conjugation. Further loss
of a formic acid produced the fragment ion at m/z 84.044. The
presence of a fragment ion at m/z 82.054 suggested that part B
was intact. Therefore, M8 was tentatively identiﬁed as a
conjugate metabolite derived from the substitution of Cl atom
by N-acetylcysteine.
Metabolite M10: Metabolites M10-1 and M10-2 were eluted
at 11.1 and 12.8 min, respectively. They had a precursor ion at
m/z 396.081, which was 176 Da higher than that of protonated
ornidazole. Their elemental composition was C13H18ClN3O9,
suggesting that they were glucuronide conjugates of ornida-
zole. The major fragment ions of M10-1 and M10-2 were at
m/z 220.049/222.047, 174.057/176.054 and 128.045. The fragment
ions at m/z 220.049/222.047 and 128.045 were identical to
Figure 5 Proposed metabolic pathways of ornidazole in human bile after intravenous doses.
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176.054 were derived from the neutral loss of a glucuronide
followed by the loss of a nitro free radical. Glucuronide could
be conjugated either on the hydroxyl group or on the nitrogen
atom of the imidazole ring. There are indications in literature
that Nþ-glucuronides are much more resistant to hydrolysis by
b-glucuronidase than some other types of glucuronides9,10.
After two kinds of common b-glucuronidase hydrolysis under
regular conditions, the intensity of the peaks corresponding to
the two metabolites remarkably decreased, and the peak of
ornidazole increased. This result suggested conjugation on the
20-hydroxyl of ornidazole. Only one glucuronide conjugate
was detected in the bile samples after intravenous infusion of
S-ornidazole, and its retention time was identical to that of
M10-1. Therefore, M10-1 and M10-2 were identiﬁed as
glucuronide conjugates on the 20-hydroxyls of S-ornidazole
and R-ornidazole, respectively.
Metabolite M11: Metabolite M11 was eluted at 7.0 min. It
showed a precursor ion at m/z 412.076 and a derived elemental
composition of C13H18ClN3O10. The fragment ions at m/z
236.044/238.040, 144.040, and 126.029 were identical to those
of M4, suggesting that M11 was a glucuronide conjugate of
M4. However, the site of conjugation was not established from
the mass spectral data.
3.3. Determination of ornidazole in human bile
An Agilent 6460 tripe quadrupole mass spectrometer equipped
with an atmospheric pressure chemical ionization source wasused for the determination of ornidazole in human bile.
Ornidazole and tinidazole (IS) formed characteristic protonated
molecules [MþH]þ at m/z 220 and m/z 248 in the positive mode,
respectively. The product ion mass spectrum of the two different
protonated molecules both showed a predominant and stable
fragment ion at m/z 128, which was chosen as the product ion
for analysis (Fig. 6). Under the given conditions, the analyte and
IS were eluted at 2.8 and 2.5 min, respectively.
The LC–MS/MS method for the determination of ornida-
zole in human bile was validated in terms of speciﬁcity,
linearity, precision, accuracy, recovery, and matrix effect.
The responses of ornidazole were found linear (R240.990)
over the concentration range of 1.00 mg/mL to 20.0 mg/mL,
with the lower limit of quantiﬁcation (LLOQ) of 1.00 mg/mL.
The intra- and inter-batche precision values for three level
quality control samples (2.00, 5.00, and 16.0 mg/mL) were less
than 11.6%, and the accuracy ranged from 3.7% to 6.7%,
as summarized in Table 2. The recoveries of ornidazole
obtained from the bile were 99.6%, 91.3%, and 98.7% at
three concentrations (2.00, 5.00, and 16.0 mg/mL), respectively.
The mean recovery for the IS was 96.7%. The matrix effects
for ornidazole at concentrations of 2.00 and 16.0 mg/mL were
100% and 96.9%, respectively. The matrix effects for the IS
was 99.9%. The results indicated that the matrix effects were
negligible.
The validated method was successfully applied in the
determination of the bile levels of ornidazole in four patients
12 h after multiple intravenous infusions of 500 mg of orni-
dazole. The results are presented in Table 3.
Table 2 Precision and accuracy of the analysis of
ornidazole in human bile (n¼3 d, 6 replicates per day).
Concertration (mg/mL) RSD (%) RE (%)
Added Found Intra-day Inter-day
2.00 1.93 5.3 11.6 3.7
5.00 4.66 6.3 9.9 6.7
16.0 15.2 3.2 3.0 4.8
Table 3 Bile levels of ornidazole in four patients 12 h
after multiple intravenous infusions of 500 mg of ornida-
zole (mg/mL).
Course Patient 1 Patient 2 Patient 3 Patient 4
Course 1a 4.36 18.8 11.1 4.88
Course 2 4.80 11.3 –b 4.68
Course 3 3.33 14.9 –b 7.43
aFirst administration of ornidazole.
bNo bile sample collection.
Figure 6 Product ion spectra of [MþH]þof ornidazole (A) and tinidazole (B).
Jiangbo Du et al.1664. Discussion
Biliary excretion is an important route for the elimination of
some drugs and metabolites in humans11. It can signiﬁcantly
affect systemic exposure to certain drugs, as well as their
pharmacological effects and toxicities12. Considering the
relative inaccessibility of human bile, feces are typically used
as a substitute to characterize the hepatobiliary elimination
of drugs. However, this method is associated with several
drawbacks. First and most important, this method cannot
distinguish between unabsorbed drug, biliary excreted drug
and drug efﬂuent from the intestine. Hence, the percentage of
the dose in feces does not necessarily reﬂect the dose excreted
into the bile. Second, relatively unstable metabolites, such as
glucuronide conjugates, may be hydrolyzed by colonic ﬂora
and enzymes in the intestine. All these drawbacks make it
difﬁcult to properly characterize the biliary excretion of drugs
using feces12,13. Therefore, the direct collection of human bile
using a T-tube in patients after biliary tract surgery enables thepossibility of fully detecting metabolites, including intact
glucuronides14,15. The method can provide a more accurate
reﬂection of the exposure of the drug and its metabolites to the
liver, gallbladder and biliary duct.
After oral administration of 750 mg of 14C-ornidazole
(49.5 mCi) to four healthy volunteers, 85% of the radioactivity
was recovered from urine and feces during the ﬁrst 5 d.
The radioactivity found in feces was 22.1% of the dose of
ornidazole4. This ﬁnding indicated that biliary excretion was
not the major excretion route of ornidazole. However, con-
sidering its extensive clinical use and large daily dose (0.5 g/d to
1.5 g/d)1, the metabolism of this drug needs to be understood
further. In the present study, human bile samples were collected
from the T-tube drainages of four patients suffering from
hepatobiliary diseases after multiple intravenous infusions of
ornidazole. The samples were analyzed by UPLC/Q-TOF MS.
A total of 12 metabolites, including 10 novel metabolites, were
detected and characterized in human bile. The metabolites of
ornidazole in human bile were the products of HCl elimination,
oxidative dechlorination, hydroxylation, sulfation, diastereoiso-
meric glucuronation, and substitution of NO2 or Cl atom by
cysteine or N-acetylcysteine, and oxidative dechlorination
followed by further carboxylation. In contrast with a previous
report5 that has identiﬁed ﬁve metabolites in human urine after
oral administration, 3-(2-methyl-5-nitro-1-imidazolyl)-1,2-pro-
panediol (M2) and 1-chloro-3-(2-hydroxymethyl-5-nitro-1-imi-
dazolyl)-2-propanol (M4) were also detected in human bile,
whereas the other three metabolites were not found. Quantita-
tively, the metabolite M7 was observed by UV detection as
the major metabolite in human bile (Fig. 3B), which was
formed by cysteine substitution of Cl. Gao et al.10 have studied
the metabolism and excretion of morinidazole in humans.
A similar metabolite of M5 derived from the substitution of
NO2 by cysteine is also detected in human urine, which
indicates that this maybe a general metabolic pathway of
nitro-imidazole-class antimicrobial agents. Further studies
should be conducted to conﬁrm these metabolites using
authentic standards and the relevant metabolic mechanisms of
the proposed pathways. Nevertheless, this result still increases
our knowledge on the metabolism of ornidazole in humans.
A total of 113 strains of anaerobic bacteria could be
inhibited by ornidazole at a concentration of 3.1 mg/mL and
could be killed at 6.3 mg/mL16. In the present study, a sensitive
and rapid LCMS/MS assay was developed and validated for
the determination of ornidazole in human bile. The bile levels
Characterization of ornidazole metabolites in human bile by UPLC/Q-TOF MS 167of ornidazole at 12 h after multiple intravenous doses were
well above 3.1 mg/mL. This ﬁnding indicated that it can be
used for the treatment and prophylaxis of susceptible anaero-
bic infections after biliary tract surgery.
The current report is the ﬁrst one on the characterization of
ornidazole metabolites in human bile. Ten novel metabolites
were found as well as characterized, and several biotransfor-
mation pathways were proposed. The bile level of ornidazole
was determined using a validated LC–MS/MS method, which
proved its clinical effectiveness.Acknowledgment
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